P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells
Cinara Echart,S. Somaini,Maria Distaso,Antonio Palumbo,Paul G. Richardson,Jawed Fareed,Massimo Iacobelli +6 more
TL;DR: Defibrotide clinical use for the prevention of DVT induced by immunomodulatory drugs is supported and the impact of thalidomide on ECs is investigated and whether DF modulates changes in fibrinolysis induced by thalidmide is investigated.
Journal ArticleDOI
Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)
Andrzej Jakubowiak,Paul G. Richardson,Todd M. Zimmerman,Melissa Alsina,Jonathan L. Kaufman,Malathi Kandarpa,Colleen K. Harvey,Kathleen Colson,Monica Mitchell,Teru Hideshima,Peter Sportelli,L. Gardner,Kathy Giusti,Kenneth C. Anderson +13 more
TL;DR: The final phase I results of this study aimed to determine the MTD and to evaluate activity of Peri + Rev + Dex, as an oral combination in patients with relapsed or refractory MM, with encouraging safety data and observed clinical activity.
Journal ArticleDOI
Marizomib for CNS-Multiple Myeloma
Ashraf Badros,Zeba N. Singh,Binod Dhakal,Young Kwok,Ann Maclaren,Paul G. Richardson,Mohit Trikha,Hari Parameswaran +7 more
TL;DR: Preliminary evidence is provided that MRZ may have utility as a therapeutic for CNS-MM and also demonstrate that combination of MRZ and daratumumab may provide benefit in this indication.
Journal ArticleDOI
Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstrom Macroglobulinemia
Irene M. Ghobrial,Fangxin Hong,Swaminathan Padmanabhan,Ashraf Badros,Meghan Rourke,Renee Leduc,Stacey Chuma,Janet Kunsman,Diane Warren,Brianna Harris,Amy Sam,Kenneth C. Anderson,Paul G. Richardson,Steven P. Treon,Edie Weller,Jeffrey Matous +15 more
TL;DR: The combination of weekly bortezomib and rituximab showed significant activity and minimal neurological toxicity in patients with relapsed WM.
Journal ArticleDOI
Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.
Meletios A. Dimopoulos,Paul G. Richardson,Rudolf Schlag,Nuriet K. Khuageva,Ofer Shpilberg,Efstathios Kastritis,Martin Kropff,Maria Teresa Petrucci,Michel Delforge,Julia Alexeeva,Rik Schots,Tamas Masszi,Maria-Victoria Mateos,William Deraedt,Kevin Liu,Andrew Cakana,Helgi van de Velde,Jesús F. San Miguel +17 more
TL;DR: Efficacy of VMP was not affected by CrCl; complete response rate, time to progression (TTP), and OS were not significantly different among patients with baseline CrCl ≤60 vs >60 mL/min, and safety profiles were comparable among Patients with CrCl of 31–60 and >60mL/min for both VMP and MP.